| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 06/03/2004 | US20040105865 Treatment and diagnosis of prostate cancer |
| 06/03/2004 | US20040105864 Food supplement |
| 06/03/2004 | US20040105862 Human TIMP-1 antibodies |
| 06/03/2004 | US20040105855 Compries immunoglobulin which binds tumor necrosis factor receptor and functions as antitumor agent in the treatment of cancer |
| 06/03/2004 | US20040105851 Treatment of tumors with superoxide dismutase for prevention by applying to tumors |
| 06/03/2004 | US20040105841 Interferons, uses and compositions related thereto |
| 06/03/2004 | DE10254336A1 Carbonsäureamide Carboxamides |
| 06/03/2004 | CA2518917A1 Pyridazinone derivatives as cdk2-inhibitors |
| 06/03/2004 | CA2506842A1 Amplification of biotin-mediated targeting |
| 06/03/2004 | CA2506724A1 Antibodies, polypeptides and uses thereof |
| 06/03/2004 | CA2506581A1 Novel 2',5'-oligoadenylic acid analogues |
| 06/03/2004 | CA2506565A1 Diazinopyrimidines |
| 06/03/2004 | CA2506503A1 Cyanoguanidines and cyanoamidines as erbb2 and egfr inhibitors |
| 06/03/2004 | CA2506245A1 Exon 1.beta. of pdgf receptor .alpha. gene and utilization thereof |
| 06/03/2004 | CA2506128A1 Anti-activated ras antibodies |
| 06/03/2004 | CA2506085A1 Combination chemotherapy comprising a mek inhibitor and capecitabine for treating cancer |
| 06/03/2004 | CA2506022A1 Pyridazinone derivatives as gsk-3beta inhibitors |
| 06/03/2004 | CA2505994A1 Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis |
| 06/03/2004 | CA2505717A1 Use of multi-specific, non-covalent complexes for targeted delivery of therapeutics |
| 06/03/2004 | CA2505377A1 Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy |
| 06/03/2004 | CA2503316A1 Method and compositions for temporarily incapacitating subjects |
| 06/03/2004 | CA2503312A1 Method and compositions for treating persistent pulmonary hypertension using aralkyl ester soft drugs |
| 06/02/2004 | EP1424557A1 Use of g protein-coupled receptor protein |
| 06/02/2004 | EP1424393A2 Mammalian cytokine-like polypeptide-10 |
| 06/02/2004 | EP1424387A1 Method of extended culture for antigen-specific cytotoxic t lymphocytes |
| 06/02/2004 | EP1424343A1 Peptide Conjugate useful for cell nucleus molecular imaging and tumor therapy |
| 06/02/2004 | EP1424330A1 Activator for peroxisome proliferator-responsive receptor delta |
| 06/02/2004 | EP1424080A1 Gnrh agonist combination drugs |
| 06/02/2004 | EP1424067A1 Injectable foam and novel pharmaceutical applications thereof |
| 06/02/2004 | EP1423739A1 Source wavelength shifting apparatus and method for delivery of one or more selected emission wavelengths |
| 06/02/2004 | EP1423702A2 PRE-mRNA SPLICING SCREENING ASSAY |
| 06/02/2004 | EP1423697A2 Secreted proteins |
| 06/02/2004 | EP1423693A1 Erythropoietin and anti-tumor necrosis factor alpha combination therapy |
| 06/02/2004 | EP1423525A1 Recombinant mva capable of expressing structural hcv antigens |
| 06/02/2004 | EP1423511A2 Nucleic-acid associated proteins |
| 06/02/2004 | EP1423510A2 Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity |
| 06/02/2004 | EP1423436A2 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids |
| 06/02/2004 | EP1423428A2 Antibodies that block receptor protein tyrosine kinase activation, methods of screening for and uses thereof |
| 06/02/2004 | EP1423425A2 Receptor, the use thereof, and mouse antibodies |
| 06/02/2004 | EP1423415A2 Intracellular signaling molecules |
| 06/02/2004 | EP1423413A1 Peptidic compounds selectively binding to p-selectin |
| 06/02/2004 | EP1423412A2 Homing peptides |
| 06/02/2004 | EP1423410A2 Peptides having a c-terminal hydroxylamino group as inhibitors of dipeptidyl peptidase i |
| 06/02/2004 | EP1423406A2 Rna interference mediated inhibition of gene expression using short interfering nucleic acid (sina) |
| 06/02/2004 | EP1423393A1 Cyclic indole and heteroindole derivatives, the production and use thereof as medicaments |
| 06/02/2004 | EP1423391A1 Pyrrolo pyrimidines as agents for the inhibition of cystein proteases |
| 06/02/2004 | EP1423390A2 Purine inhibitors of phosphodiesterase (pde) 7 |
| 06/02/2004 | EP1423386A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors |
| 06/02/2004 | EP1423384A1 Pyridine derivatives as raf kinase inhibitors |
| 06/02/2004 | EP1423383A1 Pyridine substituted furan derivatives as raf kinase inhibitors |
| 06/02/2004 | EP1423382A2 Pyrazole-derived kinase inhibitors and uses thereof |
| 06/02/2004 | EP1423381A1 17beta-hydroxysteroid dehydrogenase type 3 inhibitors for the treatment of androgen dependent diseases |
| 06/02/2004 | EP1423380A1 Pyrazole-derived kinase inhibitors and uses thereof |
| 06/02/2004 | EP1423373A2 Substituted amides, sulfonamides and ureas useful for inhibiting kinase activity |
| 06/02/2004 | EP1423370A1 Fxr nr1h4 nuclear receptor binding compounds |
| 06/02/2004 | EP1423366A1 Cyclopenta b ! indole derivatives as spla2 inhibitors |
| 06/02/2004 | EP1423169A2 Potentiator composition comprising a terpene for enhancing the therapeutical effect of antitumoral agents in the treatment of cancer |
| 06/02/2004 | EP1423140A2 Compositions and methods for modulation of immune responses |
| 06/02/2004 | EP1423135A2 Methods for inhibiting angiogenesis |
| 06/02/2004 | EP1423132A2 Complex mixtures exhibiting selective inhibition of cyclooxygenase-2 |
| 06/02/2004 | EP1423131A1 Calcium salts with cytotoxic activity |
| 06/02/2004 | EP1423126A2 Treatment of hyperproliferative conditions of body surfaces |
| 06/02/2004 | EP1423122A2 Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
| 06/02/2004 | EP1423121A1 Cysteine protease inhibitors with 2-cyano-4-amino-pyrimidine structure and cathepsin k inhibitory activity for the treatment of inflammations and other diseases |
| 06/02/2004 | EP1423120A1 2h-phthalazin-1-ones and methods for use thereof |
| 06/02/2004 | EP1423118A1 Method and composition for treatment of cancer |
| 06/02/2004 | EP1423115A2 Synthesis and anti-tumor activity of nitrogen substituted thalidomide analogs |
| 06/02/2004 | EP1423110A2 Cbi analogues of cc-1065 and the duocarmycins |
| 06/02/2004 | EP1423108A1 C-2' methylated derivatives of paclitaxel for use as antitumour agents |
| 06/02/2004 | EP1423107A2 Fatty alcohol drug conjugates |
| 06/02/2004 | EP1423105A2 Combinations of dmxaa and other anti-cancer agents |
| 06/02/2004 | EP1423103A2 Compositions and methods for modulation of darpp-32 phosphorylation |
| 06/02/2004 | EP1423099A1 A new extended release oral dosage form |
| 06/02/2004 | EP1423098A1 A new extended release oral dosage form |
| 06/02/2004 | EP1423095A1 Lipidated glycosaminoglycan particles and their use in drug and gene delivery for diagnosis and therapy |
| 06/02/2004 | EP1423080A2 Methods for treating genetically-defined proliferative disorders with hsp90 inhibitors |
| 06/02/2004 | EP1330514B1 Ex vivo oxidatively stressed cll cells in chronic lymphocytic leukemia (cll) treatment |
| 06/02/2004 | EP1227824B1 Transplant/implant device and method for its production |
| 06/02/2004 | EP1171113B1 Compounds useful as phosphotyrosine mimics |
| 06/02/2004 | EP1123097B1 Pharmaceutical composition containing decursin |
| 06/02/2004 | EP1096943B1 Method of preparation and pharmaceutical composition of an uncaria water soluble extract |
| 06/02/2004 | EP0981541B1 Psca: prostate stem cell antigen |
| 06/02/2004 | EP0941334B1 Protease-activatable pseudomonas exotoxin a-like proproteins |
| 06/02/2004 | EP0828500B1 Use of flavanolignanes for the preparation of medicaments with antiproliferative activity in uterus, ovary and breast |
| 06/02/2004 | EP0769966B1 Biotin compounds for targetting tumors and sites of infection |
| 06/02/2004 | CN1501939A Crystal of pyrimidine nucleoside derivative |
| 06/02/2004 | CN1501937A Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| 06/02/2004 | CN1501928A Small molecule compositions for binding to hsp90 |
| 06/02/2004 | CN1501915A Bipiperidinyl-derivatives and their use as chemokine receptor inhibitors |
| 06/02/2004 | CN1501827A Ligands of the alpha-v-beta 6 integrin |
| 06/02/2004 | CN1501806A Method for preparing an extract of ginkgo biloba leaves highly enriched in active principles |
| 06/02/2004 | CN1501804A Acrochordon alleviation |
| 06/02/2004 | CN1501803A Use of 2alpha-methyl-19-nor-20(s)-1alpha, 25-dihydroxyvitamin d3 to increase bone strength |
| 06/02/2004 | CN1501802A Novel use of pyrimidinyl phenylethylene sulfonamide derivative |
| 06/02/2004 | CN1501797A Anti-proliferative drugs |
| 06/02/2004 | CN1501795A Gaba-receptor modulators for the treatment of neurodegenerative diseases of the eye |
| 06/02/2004 | CN1500820A Ionic molecular conjugates of biodegradable polyesters and bioactive polypeptides |
| 06/02/2004 | CN1500808A Recombination of human soluble TRAIL protein, the preparing method and the application in preparing antineoplastic medicine |
| 06/02/2004 | CN1500803A Bc-2 antisense thiophosphoric acid oligodeoxynucleotides anticancer drugs, preparing method and uses thereof |
| 06/02/2004 | CN1500797A Preparing method for camptothecine glycoside |